TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

T cells and suppressed MM development. Altogether our data provide evidence for an immune-inhibitory role of TIGIT in MM and support the development of TIGIT-blocking strategies for the treatment of MM patients.

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma | Litlas